{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"162.0","upperLimit":"269.0","value":"215.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"description":"CD4 immune status at treatment Cycle 3.","dispersionType":"Full Range","groups":[{"description":"Patients receive cabozantinib s-malate PO QD on days 1-28 of each cycle and nivolumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 28 days for up to 1 year or 1 year after a partial response is achieved, or 6 months after a complete response is achieved in the absence of disease progression or unacceptable toxicity. Patients also undergo a CT scan and/or MRI as well as blood sample collection throughout the trial.\n\nBiospecimen Collection: Undergo blood sample collection\n\nCabozantinib S-malate: Given PO\n\nComputed Tomography: Undergo CT\n\nMagnetic Resonance Imaging: Undergo MRI\n\nNivolumab: Given IV","id":"OG000","title":"Treatment (Cabozantinib S-malate, Nivolumab)"}],"paramType":"MEDIAN","populationDescription":"Treated patients who provided samples for immune function testing.","reportingStatus":"POSTED","timeFrame":"At Treatment Cycle 3","title":"CD4 Immune Status","type":"SECONDARY","unitOfMeasure":"cells/µL"}